期刊文献+

帕金森病和阿尔茨海默氏病的基因治疗研究进展 被引量:7

Development of Gene Therapy for Parkinson's Disease And Alzheimer's Disease
原文传递
导出
摘要 帕金森病和阿尔茨海默氏病是世界范围内最普遍的神经退行性疾病。常规药物和手术治疗只能缓解症状,不能推迟或者终止疾病进程。近年来分子生物学与医学研究进展促进了对帕金森病和阿尔茨海默氏病发病机制的深入了解,为其基因治疗策略提供了理论和实验依据。综述了目前帕金森病、阿尔茨海默氏病的基因治疗研究进展。基因治疗作为帕金森病和阿尔茨海默氏病的一种全新治疗手段,无疑对于了解帕金森病和阿尔茨海默氏病的病因及其全面治疗具有重要意义。 Alzheimer's and Parkinson' s diseases represent the most prevalent neurodegenerative disorders worldwide. Current pharmacological or surgical treatments provide symptomatic benefits, but none can delay or stop the progression of these diseases. In recent years, the development of molecular biology and medicine has benefited for the understanding of Alzheimer's and Parkinson's diseases and prompted the research of gene therapy for them. An overview of the current efforts in the field for the treatment of Alzheimer' s and Parkinson' s diseases is presented. Against the pathogenesis of Parkinson' s disease and Alzheimer' s disease, there are several effective gene therapy significance for understanding Mzheimer' s disease. strategies. It is no doubt that, gene therapy, as a novel treatment, is of great the causes, as well as comprehensive treatment for Parkinson' s disease and
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2013年第4期129-135,共7页 China Biotechnology
关键词 基因治疗 帕金森病 阿尔茨海默氏病 神经退行性疾病 Gene therapy Parkinson's disease Alzheimer's disease Neurodegenerative diseases
  • 相关文献

参考文献71

  • 1Dauer W,Przedborski S.Parkinson's disease:mechanisms and model.Neuron,2003,39(6):889-909.
  • 2Rui J N,Luís P A.Gene therapy for Parkinson's and Alzheimer's diseases:from the bench to clinical trials.Current Pharmaceutical Design,2011,17(31):3434-3445.
  • 3Jankovic J.Complications and limitations of drug therapy for Parkinson's disease.Neurology,2000,55(12 Suppl 6):S2-6.
  • 4Azzouz M,Martin-Rendon E,Barber R D,et al.Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase,tyrosine hydroxylase,and GTP cyclohydrolase I induces sustained transgene expression,dopamine production,and functional improvement in a rat model of Parkinson's disease.J Neurosci,2002,22(23):10302-103012.
  • 5Muramatsu S,Fujimoto K,Ikeguchi K,et al.Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.Hum Gene Ther,2002,13(3):345-354.
  • 6Shen Y,Muramatsu S I,Ikeguchi K,et al.Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase,aromatic-L-amino-acid decarboxylase,and GTP cyclohydrolase I for gene therapy of Parkinson's disease.Hum Gene Ther,2000,11(11):1509-1519.
  • 7Oxford bioMedica announces top-line results from six month follow-up of third patient cohort in ProSavin? Phase I/II study in Parkinson's disease.Oxford Biomedica press release,2011,http://www.oxfordbiomedica.co.uk/page.asp?pageid= 59&newsid=287.
  • 8Bankiewicz K S,Forsayeth J,Eberling J L,et al.Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.Mol Ther,2006,14(4):564-5670.
  • 9Hadaczek P,Eberling J L,Pivirotto P,et al.Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Mol Ther,2010,18(8):1458-1461.
  • 10Muramatsu S,Fujimoto K,Kato S,et al.A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.Mol Ther,2010,18(9):1731-1735.

同被引文献119

引证文献7

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部